Page last updated: 2024-12-07
n,n'-diallyltartardiamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
N,N'-diallyltartardiamide: cross linking reagent; RN given refers to (R-(R*,R*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 98486 |
CHEBI ID | 184080 |
SCHEMBL ID | 107767 |
MeSH ID | M0054445 |
Synonyms (38)
Synonym |
---|
butanediamide, 2,3-dihydroxy-n,n'-di-2-propenyl- |
CBDIVE_003321 |
n,n'-diallyl-2,3-dihydroxy-butanediamide |
n~1~,n~4~-diallyl-2,3-dihydroxysuccinamide |
nsc145415 |
nsc-145415 |
28843-34-7 |
n,n'-diallyltartardiamide |
D-0950 |
datd |
n,n'-diallyltartramide |
inchi=1/c10h16n2o4/c1-3-5-11-9(15)7(13)8(14)10(16)12-6-4-2/h3-4,7-8,13-14h,1-2,5-6h2,(h,11,15)(h,12,16) |
2,3-dihydroxy-n,n'-di(prop-2-enyl)butanediamide |
zrkleahgbndkhm-uhfffaoysa- |
D1539 |
(+)-n,n'-diallyl-l-tartramide |
(+)-n,n'-diallyl-l-tartardiamide |
2,3-dihydroxy-n,n'-bis(prop-2-enyl)butanediamide |
CHEBI:184080 |
n,n'-diallyl-2,3-dihydroxysuccinamide |
(2r,3r)-2,3-dihydroxy-n,n'-bis(prop-2-enyl)butanediamide |
AKOS004903293 |
ai3-62352 |
nsc 145415 |
einecs 249-267-7 |
FT-0629377 |
FT-0629378 |
FT-0629435 |
SCHEMBL107767 |
n,n'-diallyl-l-(+)-tartardiamide |
butanediamide, 2,3-dihydroxy-n,n'-di-2-propenyl-, [r-(r*,r*)]- |
(+)-n,n'-diallyltartardiamide |
ZRKLEAHGBNDKHM-UHFFFAOYSA-N |
n,n'-diallyl tartardiamide |
butanediamide,2,3-dihydroxy-n1,n4-di-2-propen-1-yl- |
n1,n4-diallyl-2,3-dihydroxysuccinamide |
2,3-dihydroxy-n~1~,n~4~-di(prop-2-en-1-yl)butanediamide |
DTXSID50866693 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
fatty amide | A monocarboxylic acid amide derived from a fatty acid. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (11)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (54.55) | 18.7374 |
1990's | 3 (27.27) | 18.2507 |
2000's | 2 (18.18) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (9.09%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (90.91%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |